NEUCA (NEU) Stock Overview
Engages in the wholesale distribution of pharmaceuticals in Poland. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 4/6 |
NEU Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
NEUCA S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł818.00 |
| 52 Week High | zł895.00 |
| 52 Week Low | zł636.00 |
| Beta | 0.46 |
| 1 Month Change | 3.54% |
| 3 Month Change | 15.21% |
| 1 Year Change | -7.88% |
| 3 Year Change | 34.32% |
| 5 Year Change | 29.02% |
| Change since IPO | 1,793.52% |
Recent News & Updates
Recent updates
NEUCA's (WSE:NEU) Anemic Earnings Might Be Worse Than You Think
Sep 05
We Think Shareholders May Want To Consider A Review Of NEUCA S.A.'s (WSE:NEU) CEO Compensation Package
Jun 11What NEUCA S.A.'s (WSE:NEU) P/E Is Not Telling You
Dec 12NEUCA's (WSE:NEU) Performance Is Even Better Than Its Earnings Suggest
Nov 25NEUCA (WSE:NEU) Might Become A Compounding Machine
Nov 20NEUCA S.A.'s (WSE:NEU) Intrinsic Value Is Potentially 56% Above Its Share Price
Sep 19Returns On Capital At NEUCA (WSE:NEU) Have Stalled
Aug 13Risks To Shareholder Returns Are Elevated At These Prices For NEUCA S.A. (WSE:NEU)
Jul 19NEUCA (WSE:NEU) Seems To Use Debt Quite Sensibly
Mar 08Returns On Capital At NEUCA (WSE:NEU) Have Stalled
Dec 29Here's Why NEUCA (WSE:NEU) Can Manage Its Debt Responsibly
Dec 05NEUCA (WSE:NEU) Hasn't Managed To Accelerate Its Returns
Apr 16An Intrinsic Calculation For NEUCA S.A. (WSE:NEU) Suggests It's 32% Undervalued
Jan 17Capital Investment Trends At NEUCA (WSE:NEU) Look Strong
Oct 25Here's Why We Think NEUCA (WSE:NEU) Is Well Worth Watching
Aug 04Is There An Opportunity With NEUCA S.A.'s (WSE:NEU) 34% Undervaluation?
Jul 01Returns On Capital At NEUCA (WSE:NEU) Have Stalled
Jun 18NEUCA (WSE:NEU) Is Increasing Its Dividend To zł11.50
Apr 21NEUCA (WSE:NEU) Is Increasing Its Dividend To zł11.50
Apr 07NEUCA (WSE:NEU) Knows How To Allocate Capital
Mar 15Does NEUCA (WSE:NEU) Have A Healthy Balance Sheet?
Jan 03Is NEUCA (WSE:NEU) Using Too Much Debt?
Jun 14With EPS Growth And More, NEUCA (WSE:NEU) Is Interesting
May 19Investors Shouldn't Overlook NEUCA's (WSE:NEU) Impressive Returns On Capital
Mar 30A Look At The Fair Value Of NEUCA S.A. (WSE:NEU)
Mar 15Did You Participate In Any Of NEUCA's (WSE:NEU) Fantastic 211% Return ?
Mar 02Is Now The Time To Put NEUCA (WSE:NEU) On Your Watchlist?
Feb 18Is NEUCA S.A.'s(WSE:NEU) Recent Stock Performance Tethered To Its Strong Fundamentals?
Feb 06Should You Rely On NEUCA's (WSE:NEU) Earnings Growth?
Jan 26
The Case For NEUCA S.A. (WSE:NEU): Could It Be A Nice Addition To Your Dividend Portfolio?
Jan 15Is NEUCA (WSE:NEU) Using Too Much Debt?
Jan 04The Trend Of High Returns At NEUCA (WSE:NEU) Has Us Very Interested
Dec 23Is NEUCA S.A. (WSE:NEU) Trading At A 24% Discount?
Dec 13Could The NEUCA S.A. (WSE:NEU) Ownership Structure Tell Us Something Useful?
Dec 03Announcing: NEUCA (WSE:NEU) Stock Increased An Energizing 122% In The Last Three Years
Nov 23Shareholder Returns
| NEU | PL Healthcare | PL Market | |
|---|---|---|---|
| 7D | 0.4% | -1.6% | 3.0% |
| 1Y | -7.9% | 13.1% | 31.4% |
Return vs Industry: NEU underperformed the Polish Healthcare industry which returned 13.1% over the past year.
Return vs Market: NEU underperformed the Polish Market which returned 31.4% over the past year.
Price Volatility
| NEU volatility | |
|---|---|
| NEU Average Weekly Movement | 3.7% |
| Healthcare Industry Average Movement | 4.4% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in PL Market | 8.7% |
| 10% least volatile stocks in PL Market | 2.9% |
Stable Share Price: NEU has not had significant price volatility in the past 3 months compared to the Polish market.
Volatility Over Time: NEU's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 4,445 | Piotr Sucharski | www.neuca.pl |
NEUCA S.A. engages in the wholesale distribution of pharmaceuticals in Poland. It operates through Wholesale Distribution of Medicines, Manufacture of Pharmaceuticals, Medical Operator, Clinical Trials, and Insurance Activities segments. The company offers Rx, OTC drugs, dietary supplements, medical devices, dermocosmetics, hygiene products, personal protective equipment, as well as diagnostic and dressing materials under the Swiat Zdrowia, APTEO, GENOPTIM, CERA+ Solutions, and Kic Kic brands.
NEUCA S.A. Fundamentals Summary
| NEU fundamental statistics | |
|---|---|
| Market cap | zł3.66b |
| Earnings (TTM) | zł153.80m |
| Revenue (TTM) | zł13.34b |
Is NEU overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NEU income statement (TTM) | |
|---|---|
| Revenue | zł13.34b |
| Cost of Revenue | zł11.83b |
| Gross Profit | zł1.51b |
| Other Expenses | zł1.36b |
| Earnings | zł153.80m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 34.68 |
| Gross Margin | 11.31% |
| Net Profit Margin | 1.15% |
| Debt/Equity Ratio | 58.9% |
How did NEU perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/15 19:05 |
| End of Day Share Price | 2025/12/15 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
NEUCA S.A. is covered by 10 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Beata Szparaga-Wasniewska | Biuro maklerskie mBanku |
| Sylwia Jaskiewicz | Dom Maklerski Banku Ochrony Srodowiska S.A. |
| Cezary Bernatek | Erste Group Bank AG |